Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns
Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.
/ 2 items
Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.
Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.